Data is a real-time snapshot *Data is delayed at least 15 minutes. Bellerophon intends to use the net proceeds from the Offerings, together with its current cash and cash equivalents, for funding its ongoing clinical trials, working capital needs and other general corporate purposes. © 2020 CNBC LLC. To set your timezone use the location button below, or scroll through the following list... Press this button to generate a shareable image: Got a confidential news tip? For more information, please visit www.bellerophon.com. f.parentNode.insertBefore(e, f); The clinical spectrum of the COVID-19 infection ranges from mild signs of upper respiratory tract infection to severe pneumonia and death. mps._urlContainsEmail = function() { WARREN, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency expanded access allowing its proprietary inhaled nitric oxide (iNO) delivery system, INOpulse®, to immediately be used for the treatment of COVID-19. if(typeof document.getElementsByTagName('meta')['tp:PreferredRuntimes'] === 'object') { Importantly, INOpulse is designed to treat patients in the outpatient setting, which may be critical in helping combat the further spread of the virus and significantly alleviate the mounting impact on hospitals and intensive care units. Bellerophon Therapeutics announced that the first patient has initiated treatment in the Company's Phase 3 clinical study of INOpulse inhaled nitric oxide therapy for the treatment of COVID-19 at Banner University Medical Center, within the University of Arizona College of Medicine - Phoenix, under the direction of Dr. Thomas Ardiles, clinical assistant professor and Dr. Marilyn Glassberg, professor of medicine and chief of the Pulmonary, Critical Care and Sleep Division. Under the recently completed EAP, 180 hospitalized patients with COVID-19 from 18 hospitals across the United States received treatment with INOpulse under the care and supervision of their physicians. “Based on currently available data and its significant role in the immune response, we believe INOpulse has the potential to be a safe and effective treatment for COVID-19,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon.
Any statements in this press release about Bellerophon’s future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. } We want to hear from you. var _regex = /([^=&/<>()[].,;:s@"]+(.[^=&/<>()[].,;:s@"]+)*)@(([[0-9]{1,3}.[0-9]{1,3}.[0-9]{1,3}.[0-9]{1,3}])|(([a-zA-Z-0-9]+. ContactsAt Bellerophon: Fabian Tenenbaum, Chief Executive Officer (908) 574-4767, At LifeSci Advisors:Brian Ritchie(212) 915-2578britchie@lifesciadvisors.com. var pixelurl = ((document.location.protocol === 'https') ? The trial initiation follows highly encouraging preliminary data generated from 180 hospitalized COVID-19 patients treated under our recently completed Emergency Expanded Access Program." Bellerophon Therapeutics (NASDAQ BLPH) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance